Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Recursion Pharmaceuticals

AI holds tremendous promise for the biopharma industry. Using AI to identify candidates for new drugs is already happening.

Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks

Ginkgo provides update on its restructuring process including estimated annualized cost savings of over $85 million from reduction in force  BOSTON , Aug. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2024. The update, including a webcast slide presentation with additional details on the second quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

Ginkgo Bioworks Reports Second Quarter 2024 Financial Results

The Global Agriculture Biologicals Testing Market Size was Valued at USD 2.80 Billion in 2023 and the Worldwide Agriculture Biologicals Testing Market Size is Expected to Reach USD 5.61 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: ALS Group, Anadiag Group, Bionema Group Limited, BioTecnologie BT, Eurofins APAL Pty Ltd, Eurofins Scientific SE, i2LResearch, Lallemand Inc., LAUS GmbH, R J Hill Laboratories Limited, SGS SA, Staphyt SA, SynTech Research Group, and Others The Global Agriculture Biologicals Testing Market Size was Valued at USD 2.80 Billion in 2023 and the Worldwide Agriculture Biologicals Testing Market Size is Expected to Reach USD 5.61 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: ALS Group, Anadiag Group, Bionema Group Limited, BioTecnologie BT, Eurofins APAL Pty Ltd, Eurofins Scientific SE, i2LResearch, Lallemand Inc., LAUS GmbH, R J Hill Laboratories Limited, SGS SA, Staphyt SA, SynTech Research Group, and Others

Global Agriculture Biologicals Testing Market Size To Worth USD 5.61 Billion by 2033 | CAGR of 7.20%

Ginkgo Bioworks (NYSE: DNA ) stock is falling on Friday after the cell programming company announced plans for a reverse split of its shares. Ginkgo Bioworks wants to enact a reverse stock split for DNA shares in the range of one-for-20 to one-for-40.

DNA Stock Alert: Ginkgo Bioworks Plunges on Plan for Reverse Stock Split

Special meeting to take place virtually on August 14, 2024 at 4:00 pm ET BOSTON, Aug. 2, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, will be holding a special meeting of shareholders virtually on August 14, 2024 at 4:00 pm ET to vote to permit, at the discretion of the Board of Directors, a reverse stock split of the issued and outstanding shares of Class A common stock and Class B common stock in a range of not less than one-for-twenty (1:20) and not more than one-for-forty (1:40), with the final ratio to be determined by the Board of Directors. Shareholders will also vote to approve Ginkgo's Amended and Restated Certificate of Incorporation, which has been updated to permit officer exculpation and remove provisions related to our merger with Soaring Eagle Acquisition Corp. and our domestication process, which are no longer relevant to our business.

Ginkgo Bioworks to Hold Special Meeting of Shareholders

Presentation and Q&A session scheduled for post-market on Thursday, August 8, 2024 BOSTON , Aug. 1, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2024, on Thursday, August 8, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.

Ginkgo Bioworks Announces Date of Second Quarter 2024 Results Presentation

Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $0.37, signifying a +0.3% move from its prior day's close.

Ginkgo Bioworks Holdings, Inc. (DNA) Advances While Market Declines: Some Information for Investors

The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $0.30, representing a +0.6% change from its previous close.

Why the Market Dipped But Ginkgo Bioworks Holdings, Inc. (DNA) Gained Today

NEW YORK , July 23, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) on behalf of the company's shareholders. The investigation seeks to determine whether Ginkgo's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA)

AMC Entertainment

Beyond Meat

ChargePoint Holdings

GameStop

Rivian Automotive

SoundHound AI Inc

Meme stocks, fueled by social media hype, can soar or crash rapidly. While some see potential for explosive gains, others pose a high risk.

7 Meme Mania Stocks: Which Are FOMO and Which Are Free Money?

Ginkgo Bioworks Holdings (NYSE: DNA ), which develops platforms for cell programming, has multiple, positive potential catalysts and a rather low valuation. Moreover, the shares should benefit from investors' recent interest in buying small-cap stocks that have lost a great deal of their value.

AI Demand and New Deals Make Ginkgo Bioworks Stock a Speculative Buy

Biotechnology specialist Ginkgo Bioworks (NYSE: DNA ) is seeing shares skyrocket today following an announcement of a potentially lucrative collaboration. Specifically, Ginkgo will partner with Syngenta, which is billed as a “leader in agricultural innovation.

DNA Stock: Ginkgo Bioworks Announces New Collaboration

BASEL, Switzerland & BOSTON--(BUSINESS WIRE)--Syngenta Crop Protection, a leader in agricultural innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new cooperation aimed at accelerating the launch of a new biological solution. The two companies have previously collaborated on next-generation seed technology. Through this new collaboration, Ginkgo plans to develop and optimize a microbial strain that can mee.

Syngenta collaborates with Ginkgo Bioworks to enable faster launch of innovative biologicals

Ginkgo Bioworks is scaling down its workforce and operating footprint. It's also aiming to restrict the scope of the services it offers.

Down 81% in 2024, Is Ginkgo Bioworks Stock Still a Buy?

The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $0.32, representing a -1.51% change from its previous close.

Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Engine Media Holdings

It's crucial to steer clear of potential pitfalls that could sink your portfolio. With the S&P 500 and Nasdaq posting impressive year-to-date gains, it's tempting to get caught up in the bullish fervor.

3 Stocks to Avoid Like the Plague in 2024

Allbirds

Village Farms International

High-risk penny stocks are known for their volatility. They often feature low trading volumes, minimal prices and unstable financial and fundamental standings.

3 High-Risk, Sky-High Reward Stocks to Buy for Under $1

There's definitely a science to picking beaten-down gems in the stock market. If you get it wrong, you could lose a lot of money.

Stay Away: Why Ginkgo Bioworks Stock Is Not for the Faint-Hearted

Moderna

Cassava Sciences Inc

The biotech segment is a relatively new sector that combines the fields of biology and technology. It integrates natural sciences from biology and engineering aspects from technology to develop products with meaningful applications in areas like medicine, agriculture, therapeutics, and more.

3 Biotech Stocks to Sell in July Before They Crash & Burn

CRISPR Therapeutics

In 2024, the iShares Biotechnology ETF (NASDAQ: IBB ) is up just over 1.5%. If you're looking for steady, dividend-paying stocks, you can find a number of biotech stocks to buy from the holdings in this fund.

Rags to Riches: 3 Biotech Stocks That Could Make Early Investors Rich

Ginkgo Bioworks (NYSE: DNA ) layoffs continue today with the cell programming company announcing additional job cuts. The latest update to the Ginkgo Bioworks layoffs reveals that the company is planning to cut at least 35% of its workers.

Ginkgo Bioworks Layoffs Expand to 400 Job Cuts

Ginkgo Bioworks continued its slide from earlier in the week. The company is cutting 25% of its workforce.

Why Ginkgo Bioworks Stock Is Sinking Today

Ginkgo Bioworks (NYSE: DNA ) layoffs are coming for 158 of the company's employees and more are on the way. Ginkgo Bioworks has revealed that it's going to be cutting 158 jobs as part of its effort to reduce its labor costs by 25%.

Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts

Archer Aviation

Rocket Lab USA

Investing in penny stocks can reward bold, patient investors. But patience can be in short supply when you can just buy NVIDIA (NASDAQ: NVDA ) and sleep well at night.

5-Year Fortune Forecast: 3 Penny Stocks Destined for Massive Gains

FuelCell Energy

Faraday Future Intelligent Electric

MicroVision

Nikola

Tellurian

The stock market continues to climb. But in this case, a rising tide isn't necessarily lifting all boats.

News for Ginkgo Bioworks Holdings Stock (DNA)